BioStock: Alligator Bioscience awarded Orphan Drug Designation for mitazalimab

Lund-based Alligator Bioscience continues to increase the value of its lead asset mitazalimab. The company recently announced receiving Orphan Drug Designation for the CD-40 antibody from the FDA. BioStock contacted Jonas Henningsen, VP Regulatory Affairs at Alligator, and CEO Søren Bregenholt, to learn more about what this means for the project.

Read the interview with Jonas Henningsen and Søren Bregenholt at biostock.se:

Alligator Bioscience awarded Orphan Drug Designation for mitazalimab - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/